HESA Committee Report
If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.
APPENDIX A: LIST OF WITNESSES
The following table lists the witnesses who appeared before the Committee at its meetings related to this report. Transcripts of all public meetings related to this report are available on the Committee’s webpage for this study.
Organizations and Individuals |
Date |
Meeting |
Amyotrophic Lateral Sclerosis Society of Canada Tammy Moore, Chief Executive Officer |
2018/09/27 |
112 |
Canadian Organization for Rare Disorders Maureen Smith, Board Secretary Durhane Wong-Rieger, President and Chief Executive Officer |
2018/09/27 |
112 |
Department of Health Catherine Parker, Director General, Biologics and Genetic Therapies Directorate, Health Products and Food Branch Karen Reynolds, Executive Director, Office of Pharmaceuticals Management Strategies John Patrick Stewart, Director General, Therapeutic Products Directorate |
2018/09/27 |
112 |
As individuals Craig Campbell, MD, Department Pediatrics and Neurology, Children's Hospital London Health Sciences Centre Doug Coyle, Professor, School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa Julian Midgley, Paediatric Nephrologist |
2018/10/04 |
114 |
The Isaac Foundation Andrew McFadyen, Executive Director |
2018/10/04 |
114 |
As individuals Michael Brudno, Professor and Scientific Director, Centre for Computational Medicine, Hospital for Sick Children Joel Lexchin, Professor Emeritus, School of Health Policy and Management, York University Ian Stedman, Osgoode Hall Law School, York University |
2018/10/25 |
118 |
Children's Hospital of Eastern Ontario (CHEO) Alex MacKenzie, Clinician Scientist |
2018/10/25 |
118 |
Janssen Inc. Pharmaceutical Companies of Johnson & Johnson Jacqueline Dobson, Government Affairs and Policy Manager, Government Affairs and Market Access Stacey Silverberg, Stakeholder Engagement Manager, Government Affairs and Market Access |
2018/10/25 |
118 |
Atypical Hemolytic Uremic Syndrome Canada Mary Jane Vowles, Board Member Caryn Vowles, Board Member |
2018/10/30 |
119 |
Department of Health Catherine Parker, Director General, Biologics and Genetic Therapies Directorate, Health Products and Food Branch Karen Reynolds, Executive Director, Office of Pharmaceuticals Management Strategies John Patrick Stewart, Director General, Therapeutic Products Directorate |
2018/10/30 |
119 |
Liv-A-Little Foundation Erin Little, President |
2018/10/30 |
119 |
Canadian Agency for Drugs and Technologies in Health Heather Logan, Acting Vice-President, Pharmaceutical Reviews |
2018/11/06 |
121 |
Patented Medicine Prices Review Board Douglas Clark, Executive Director |
2018/11/06 |
121 |